Galunisertib: Phase II data

Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.
Product: Galunisertib ( LY2157299)
Business: Cancer
Molecular target: Transforming growth factor

Read the full 180 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE